[Monoamine oxidase inhibitor in the treatment of attention deficit disorder of residual type. Apropos of a case].
Attention deficit disorder is common in children and it may continue during adolescence and adulthood. Some psychotropic drugs can improve the social, school and professional adaptation. A 16 year old girl suffering from an attention deficit disorder of the residual type according to the DSM III criteria was treated by toloxatone, a new monoamine oxidase inhibitor. According to clinical improvement observed with this drug, it may be considered as a new symptomatic treatment of this disorder.
Parquet
P J
PJ
Service de Psychiatrie Infanto-Juvénile, CHR de Lille.
Servant
D
D
Bailly
D
D
Meurice
J P
JP
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010080:Oxazoles / Q000627:therapeutic use*; D023303:Oxazolidinones
D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D023303:Oxazolidinones; C010798:toloxatone
Inhibiteur de la monoamine oxydase dans le traitement du trouble déficitaire de l'attention--type résiduel. A propos d'une observation.